Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment by Araujo, Leila Fernandes et al.
Vascular Health and Risk Management 2006:2(4) 465–475




Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Blood Institute (NHLBI) released in 2004 an executive
summary in which a strategy for cardiovascular research and
education for women must be developed. A number of targets
were set in a few different areas, such as improving
understanding of pathology and pathophysiology of gender
differences in ischemic heart disease (IHD), improving
understanding of symptom description and diagnostic tools,
conducting gender-specific clinical investigation, investigating
mechanisms for adverse cardiovascular events in an early
phase of hormone replacement therapy (HRT) and promotion
of translation research––approaches into actual practice (Merz
et al 2004).
It is recognized that a better understanding of the these
topics is necessary for a meaningful communication between
public, patients, and healthcare professionals. The aim of this
paper will be to review the literature on the subject of CVD in
women. The review will be in four sections, the first section
will focus on contributions on mechanisms of pathophysiology,
diagnosis, and treatment. The second section will concentrate
on well known risk factors and novel risk markers. This will be
followed by a section emphasizing new recommendations for
clinical practice. Subsequently, attention will turn to preventive
strategies recently established and recommendations for future
research. The literature here reviewed leads to a request for
future research regarding all steps of CVD evaluation,
treatment and prevention focused on the female population.
Pathophysiology, diagnosis,
and treatment of cvd in women
Diagnosis-related outcomes
Even though more women die of CVD than from all forms of
cancer combined (American Heart Association 2003), this
condition is seen as only a remote health risk by the public.
Moreover, the functional expression and the disability caused
in women by obstructive CAD are much greater when
compared to men (Merz et al 2004). Yet, due to the incomplete
understanding of gender-specific pathophysiology of
ischemia and underdeveloped diagnosis and treatment
strategies, a large number of women without obstructive CAD
at coronary angiography present symptom-related disability
and thus consume a considerable amount of healthcare
resources (Merz et al 2004).
Diagnosis of the illness in women remains underdeveloped.
One of the reasons is that chest pain in women is less likely to
be related to flow-limiting coronary stenosis than chest pain
in men (Kennedy et al 1982; Diamond et al 1983; Merz et al
1999), and the main instrument used to search for the cause of
chest pain is still coronary angiography. In addition, it is the
diagnosis of ischemia that will determine the patient’s
prognosis (Merz et al 2004).
The detection of unstable angina carries a much more
severe prognosis than chronic stable angina. On the other
hand, the detection of angina does not carry an increased risk
of infarction or sudden cardiac death, and the relevance of
such detection lies on the knowledge of its causes and of
what can be done to treat them (Maseri 2004).
Syndrome X is a typical condition that illustrates the
challenge of the diagnosis of myocardial ischemia. It has a
10%–15% incidence in patients submitted to coronary
angiography and is characterized as angina pectoris and
normal coronary angiography (Maseri 2004). Such criteria
include heterogeneous patients with and without cardiac origin
of pain, which turns diagnosis of myocardial ischemia even
more difficult.
A new program which has been initiated by the WISE
study researchers is designed to examine the outcome from
all patients that present themselve at emergency department
with their very first manifestation of IHD (Maseri 2004). The
ongoing study relies on a standardized questionnaire focused
on possible differences in symptoms and presentation for
each of the various ischemic syndromes. A blood sample is
obtained for traditional risk factors and a sample is stored in
biological banks. All patients undergo clinically required tests
and interventions, special pathogenic studies, and join a
regular follow-up program that will identify patients with
different outcomes. These efforts are aimed at obtaining new
information on pathogenic mechanisms and on predisposing
and protective factors, which will be used for developing
novel, rational treatment strategies for patients with IHD. It is
expected that this study will reveal important information since
a lack of appropriate diagnosis can have a devastating effect
on the long-term health of patients.
Stable angina
The traditional view of the chronic stable ischemia syndrome
was related to typical effort-induced angina pectoris (Pepine
2004). This view consisted of reversible myocardial ischemia,
caused by obstructive CAD that limits blood flow during
periods of increased myocardial oxygen demand. It was
believed that dynamic changes in coronary blood vessel size
were infrequent and contributed little to the etiology, as well
as microcirculation was thought to be relatively spared from
this disease. This syndrome did not appear to afflict womenVascular Health and Risk Management 2006:2(4) 467
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until they became elderly with the exception of diabetic women
(Friedberg 1966).
A more contemporary view includes variable thresholds
for ischemia and symptoms that may vary. This view involves
ischemia due to dynamic changes in coronary size that also
compromise the microcirculation (Panting et al 2002).
Endothelial dysfunction, and higher risk of atherosclerosis is
prevalent in women with hypertension, diabetes, and
dyslipidemia (Quyyumi 1998).
Once again regarding the WISE workshop, symptom
recognition should evolve. Coronary angiography has limited
symptom assessment, since it depends on the prevalence of
obstructive CAD (Pepine et al 2004). Prior literature illustrates
that women referred for angiography have lower likelihood of
obstructive CAD than men (Diamond 1984). In the WISE study,
only 39% of the women had CAD, defined as over 50%
stenosis, in more than one coronary artery. In addition,
evidence from the Coronary Artery Surgery Study (CASS)
demonstrated that although typical angina was predictive of
CAD in both men and women, the higher prevalence of non-
obstructive CAD in women compared with men suggested
that symptoms were less diagnostic in the female group
(Kennedy et al 1982). Furthermore WISE investigators found
that the typical angina classification missed 65% of women
who actually had CAD. Symptoms experienced by women
without CAD may be related to microvascular ischemia or
constriction of coronary arteries (Johnson et al 2003).
The American Heart Association (AHA) approved, in 2003,
the publication of a summary that points out new methods in
evaluating women with chest pain (Pepine 2004). According
to this article, several studies demonstrate the limited value in
women undergoing evaluation for CAD of standard stress
testing and evaluation of electrocardiographic changes,
myocardial perfusion defects, and regional wall motion
abnormalities. The document determines perfusion imaging
with magnetic resonance imaging (MRI) and magnetic
resonance spectroscopy (MRS) as feasible methods for chest
pain evaluation. The first method has shown evidence of
subendocardial hypoperfusion in the absence of large-vessel
obstruction, whereas the MRS also has the potential to detect
myocardial ischemia by demonstrating transient reduction in
myocardial high energy phosphates and increases in organic
phosphate during stress testing. Nevertheless, the
Association proposes additional studies to determine their
diagnostic accuracy.
Carotid ultrasound, MRI, and test on the functionalty
of endothelium have advantages over other invasive
techniques in detecting atherosclerosis in its earliest stages.
On the other hand, such screening requires sophisticated
equipment and skillful expertise (Pepine 2004). Regarding
the invasive techniques, intravascular ultrasound (IVUS)
not only visualizes coronary lumen, as does coronary
angiography, but also arterial wall characteristics. The WISE
IVUS substudy has released preliminary data suggesting
that the majority of women without flow limiting lesions had
abnormalities of endothelial function and/or microvascular
flow reserve, with the potential to limit coronary perfusion
(Tuzcu et al 1996).
Therefore, a better comprehension of the patho-
physiologic mechanisms of stable angina in the female
population can improve symptom recognition, which leads to
more appropriate treatment strategies. It is such an effort that
will help minimize deaths or disabilities caused by the disease.
Acute cardiac ischemia
Substantial scientific information on acute cardiac ischemia
(ACI) has been available in scientific literature for many years.
However, the diagnosis and treatment are far from the finest,
as women tend to present to the emergency department at
older ages, with more comorbidity and with differences in
symptoms when compared with men (Jayes et al 1992;
Coronado et al 1997; Maynard et al 1997; Zucker et al 1997;
Pope et al 1998; Milner et al 1999; Goldberg et al 2000). Missed
diagnosis and treatment lead to unnecessary deaths.
A recent study on diagnosis and treatment on ACI
from the NHLBI
 (Nabel et al 2004) recommends improvement
in four different domains with the intention of improving
healthcare in this area. These recommendations begin with
effectiveness of the diagnosis, which consists of “a need to
develop and test ways to improve use of existing diagnostic
methods and new ways of diagnosing ACI in women, not
only by Emergency Department by physicians, but also by
prehospital, nonhospital, and nonphysician clinicians”. The
next recommendation is the effectiveness of treatment that
like above, depends on development and testing of methods
to improve treatment and decision making in management of
women with ACI. The document also acknowledges the
importance of dissemination and communication of the best
use of effective diagnostic technologies and improved
treatment strategies in order to translate them into actual
practice. Finally, the understanding of the disease is necessary
to communicate the right message to all public, patients and
healthcare professionals. Moreover, the same document
recommends that the better understanding should come
together with research, for example, on prodromal syndromesVascular Health and Risk Management 2006:2(4) 468
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for ACI, in which all patients would be questioned about
presenting symptoms and signs in the early stages of the
disease.
All these recommendations represent a growing trend in
the recognition and treatment of ACS, leading to a significant
lowering of the rate of mortality in patients with CAD.
Innovations on traditional risk
factors and novel risk markers
in CVD in women
The effects of aging, dyslipidemia, hypertension, cigarette
smoking, and diabetes, among other risk factors, promote the
sequelae of endothelial dysfunction, inflammation, and
atheromatous plaque deposition in women, as well as men.
The five risk factors mentioned above are all well known
traditional risk factors and their correlation to pathophysiology
of CAD has been well documented (Sharret et al 2001).
Moreover, several novel risk markers have been identified
over the past 10 years, which include new forms of lipid
particles, metabolites, hemostatic factors, and inflammatory
markers. Acknowledged risk markers such as C-reactive protein
(Bayes-Genis et al 2001) and Pregnancy Associated Plasma
Protein (Coronado et al 1997) help identify patients with
ischemic syndromes and provide better insight into the arterial
dysfunction as well as on the underlying risk. A document on
CAD risks from the WISE workshop (Shaw et al 2004) asserts
that these are best classified as risk markers rather than risk
factors because causal status has not yet been established
unequivocally, even though it appears that they contribute to
underlying pathophysiological processes. In that manner,
novel studies include not only new scientific information on
the traditional risk factors but also the latest acknowledgments
and future research suggestions on the recently proposed
risk markers.
Traditional risk factors
The Atherosclerosis Risk In Communities (ARIC) study
assembled over 15 thousand middle-aged men and women
and analyzed their traditional risks for CAD (ie, age, cholesterol
levels, blood pressure levels, smoking habit, and diabetes)
with the intention of building a global risk score to predict a
10-year risk of CAD events (Hubbard et al 1999; Wong et al
2002). This study has determined that the equations relating
the risk factors have higher predictive values in women than
in men and also non-traditional risk factors and subclinical
atherosclerosis measures improve prediction only in the male
population.
Diet and lifestyle
Many of the scientific gains on the subject of CVD include
improvement in pharmacological therapies and surgical
interventions, which have most certainly helped to decrease
related mortality. Nevertheless these treatments are expensive,
present various side effects, and require medical intervention.
Against this background, a cohort study was developed in
the US, the Nurses’ Health Study, proving that the adherence
to lifestyle guidelines involving diet, exercise, and abstinence
from smoking is associated with a very small risk of CAD
while appropriate adjustments were made for age, family
history, hypertension, dyslipidemia, and menopausal status
(Stampfer et al 2000).
The Nurses’ Study included over 84000 US female nurses
who were free of CVD, cancer, and diabetes and were followed
for 14 years. Low-risk subjects were defined as “those who
were currently not smoking, had a body mass index under 25
kg/m
2, consumed an average of at least half a drink of an
alcoholic beverage per day, engaged in moderate-to-vigorous
physical activity (which could include brisk walking) for at
least half an hour per day on average, and scored in the highest
40% of the cohort for consumption of a diet high in cereal
fiber, marine n-3 fatty acids, and folate, with a high ratio of
polyunsaturated to saturated fat, and low in trans fat and
glycemic load, which reflects the extent to which diet raises
blood glucose levels (Stampfer et al 2000).
Only 3% of the population were in the low-risk category,
and when compared with all other women this percentage had
a relative risk of coronary events of 0.17. This index suggests
that if all women had been in the low-risk group, 82% of the
coronary events would have been prevented. The most
important risk factor was cigarette smoking: women who
smoked 15 or more cigarettes per day and had a relative risk of
5.48 compared with non-smokers. It was emphasized that even
women who smoke 1 to 14 cigarettes per day have a tripled
risk of coronary event. It is also evident that the rising
incidence of obesity in various occidental countries points a
high body-mass index (BMI) as another important female-
specific risk factor. The risk was found to increase when the
BMI exceeded 23 kg/m
2, reaching a relative risk of 1.57 for
BMI above 30 kg/m2. In addition, each individual component
of the low-risk profile (ie, dietary score, exercise, body-mass
index, smoking, and alcohol consumption) showed a
significant and substantial association with risk, and theVascular Health and Risk Management 2006:2(4) 469
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elevation of the risk gradient was related to the presence of a
crescent number of components (Stampfer et al 2000).
The Nurse’s Health Study is an important etiologic study.
It illustrates the benefits of simple interventions in the
prevention of a substantial number of CAD events in women.
Anemia
For both men and women, limited coronary flow caused by
coronary artery obstruction, and endothelial and/or
microvascular dysfunction can be worsened by low
hemoglobin (Hgb) levels (Arant et al 2004). Recent studies
suggest that decreased Hgb is an independent predictor of
increased morbidity and mortality in patients presenting with
acute myocardial infarction (AMI) (Wu et al 2001; Al Falluji et
al 2002; Sarnak et al 2002).
Iron deficiency is an important public health issue.
Approximately 2%–5% of American teenage girls are
sufficiently iron-deficient
 to have anemia and more than half a
billion people worldwide are at the risk of adverse effects as a
result of iron deficiency (Andrews 1999). Anemia has been
documented in approximately 15% of patients presenting with
AMI and in 43% of elderly patients that present with the latter
medical condition (Chesebro et al 1987; Wu et al 2001).
Two mechanisms are believed to worsen the ischemic insult
in the myocardium in AMI and other ACS: decreased oxygen
content of the blood supplied to the myocardium (Most et al
1986) and increased myocardial oxygen demand, due to a
higher cardiac output, necessary to maintain adequate
systemic oxygen delivery (Levy et al 1996).
Anemia has been shown to be an independent risk factor
for adverse cardiovascular outcomes in community cohorts
(Sarnak et al 2002), in patients with heart failure (Al-Ahmad et
al 2001; Ezekowitz et al 2003), and in patients undergoing
percutaneous coronary intervention (McKechnie et al 2004).
More recent studies have been designed to relate anemia to
clinical outcomes in patients with ACS.
Sabatine et al (2005) examined the association between
baseline Hgb and major adverse cardiovascular events
through 30 days in almost 40000 patients with ACS. In patients
with ST-elevation AMI, Hgb between 14 and 15 g/dL were used
as reference, and cardiovascular mortality increased as Hgb
fell below 14 g/dL, with an adjusted odds ratio (OR) of 1.21 (p
< 0.001) for each 1 g/dL decrement in Hgb. Patients with non-
ST-elevation ACS (reference Hgb 15–16 g/dL) also had an
increased rate of death or ischemic events, as Hgb fell below
11 g/dL, with an adjusted OR of 1.45 (p < 0.001) for each 1 g/
dL. Hemoglobin higher than 16 g/dL was also seen to increase
adverse cardiovascular events. The association of lower Hgb
with short-term mortality in patients with AMI was confirmed
by Lipsic et al (2005) in which a hazard ratio (HR) of 1.76 (p =
0.02) was demonstrated for patients with Hgb < 10 g/dL.
The association between anemia and adverse cardiovascular
outcomes was also verified in lorger-term follow-up studies.
Langston et al (2003) demonstrated a mortality rate at one
year after AMI of 30.7% (OR 1.35: p = 0.0067) for hematocrit
between 30% and 35%. Vaglio et al (2005) assessed a two-
year survival rate among patients who had ACS that were
classified by discharge hematocrit values. Worsening anemia
was associated with a decreased 2-year survival rate, with a
HR of 2.46 (p = 0.025) in patients with moderate/severe anemia
(hematocrit < 33%).
An interesting new prospective study developed as part
of the WISE study linking lower Hgb with higher risk for
adverse cardiovascular outcomes, to women with ischemic-
type symptoms, regardless of the presence or severity of CAD
(Arant et al 2004). According to this study, such association
appears with only a modest reduction in Hgb during
intermediate term follow-up. Hemoglobin levels were compared
with cardiovascular risk factors, core laboratory interpreted
angiograms, inflammatory markers, and adverse cardiovascular
outcomes. The researchers affirmed lower Hgb in women
presenting with ischemic-type symptoms which was
significantly and independently associated with adverse
cardiovascular outcome (Arant et al 2004).
Regarding yet unknown prognostic importance and
prevalence of low Hgb in the female population, researchers
recommend further study on pathophysiology and benefits
of intervention in these women with suspected ischemia.
Although previous research suggests that patients with low
hematocrit who receive transfusions had improved outcomes
(Wu et al 2001; Al Falluji et al 2002; Sarnak et al 2002), while
Rao et al (2004) associated blood transfusion in the setting of
ACS with higher mortality. Specific therapeutic strategies
should be considered in anemic ACS patients.
Oral contraceptives
The use of oral contraceptives (OC) has been associated with
an increased risk of atherosclerosis as well as venous
thrombosis since their introduction in clinical practice (Tanis
et al 2003). Many efforts have been made in order to lower
such risks by reducing estrogen dosage and modifying the
progestagen compound. Over 100 million women use OC
worldwide (Tanis et al 2003), which makes safety a matter of
great importance. Of note is an interesting case-control studyVascular Health and Risk Management 2006:2(4) 470
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that was developed in the Netherlands to investigate the
association between the risk of myocardial infarction and the
use of OC, according to the type of progestagen, the dose of
estrogen, and the presence or absence of prothrombotic
mutations. The data revealed a 2-fold increased risk of AMI
among users of any type of OC, whereas the relative risk of
OC users with no conventional risk factors was 3.1 when
compared with non-users (Tanis et al 2001). When different
generations of these medications were compared, the risk for
AMI for those who used second-generation contraceptives
was increased by a factor of 2.5 while third-generation OC did
not increase the risk significantly (OR1.3), suggesting a lower
risk, but the overall findings remain inconclusive. The
generation is defined by type of progestagen: second
generation includes levonorgestrel and third generation
includes desogestrel and gestodene. The prothrombotic
mutation did not alter the risks. It was concluded that the
recommendation to clinicians should be to screen for traditional
cardiovascular risk factors and events before prescribing OC
(Tanis et al 2001). The recommendation was based on the
alarming figures found: the odds ratio among OC users who
smoked was 13.6, among diabetic women 17.4, and those with
dyslipidemia 24 (Tanis et al 2001).
A later publication (Tanis et al 2003) suggests that the
inconclusive benefits of third generation OC concerning AMI
do not counterbalance the adverse effect of this generation
on venous thrombosis.
Pregnancy
Another risk factor related to CAD in women is parity. Pregnancy
exaggerates atherogenic responses, including insulin resistance
and dyslipidemia, manifesting as preeclampsia and gestational
diabetes. These complications increase the post-partum risk of
CVD, with a 2-fold increased risk of CAD and cerebrovascular
disease (Kaaja and Greer 2005). It has been shown that women
with gestational diabetes can progress to type 2 diabetes mellitus
(Kaaja and Greer 2005). In many studies the conversion from
gestational diabetes to type 2 diabetes has been variable, but
the long-term (>10 year) risk is approximately 70% (Buchanan
and Xiang 2005). Pre-eclampsia is associated with insulin
resistance, as well as hypertension, lower high density
lipoprotein (HDL) concentrations, higher plasma levels of
triglycerides, uric acid, and insulin. It is also recognized as a
state of sympathetic overactivity and proinflammatory changes
(Kaaja and Greer 2005). Thus, pre-eclampsia may be the first
manifestation of the metabolic syndrome. A large Scottish study
(Smith et al 2001) found a significant association between
preeclampsia and maternal hospital admission for ischemic heart
disease or death (hazard ratio 2.0; 95% CI 1.5–2.5).
Pregnancy also increases the risk of venous thrombosis
by 7- to 10-fold (Martinelli et al 2002). This risk is approximately
3-fold higher than that associated with OC use (Wu et al 2005).
There is also a 50% increase in plasma volume, which can
unmask glomerulopathies, peripartum cardiomyopathy, arterial
aneurisms, or ateriovenous malformations (Kaaja and Greer
2005).
An association between number of children and CAD risk
factors and prevalent CAD in women and men aged 60–79 has
also been established (Lawlor et al 2003). The comparison of
gender indexes determines whether the association is due to
biological processes or lifestyle factors. The results include
association of increasing number of children and increasing
obesity in both sexes. In women only, some association was
found between number of children and CAD after adjustment
for obesity and metabolic factors. Before the adjustment, both
sexes showed an increasing risk of cardiac events: after the
second pregnancy, each additional child increased the age-
adjusted odds for CAD in by 30% (OR 1.3; 95% confidence
interval [CI] 1.17–1.44) for women and 12% (OR 1.12; 95% CI
1.02–1.22) for men.The biological mechanisms for the association
are still unclear. Some possibilities include a reduced lifetime
exposure to estrogen due to pregnancy “resets” of ovarian
function as well as a permanent effect on lipid and glucose
metabolism resulting from repeated pregnancy-induced insulin
resistance (Rossouw et al 2002).
Pregnancy can reveal preexisting risk factors for metabolic
syndrome and CVD, which makes these women appropriate
candidates for careful screening of CVD risk factors and for
possible interventions. Primary prevention should be
considered after pregnancy for these high risk individuals.
Menopause and hormone replacement
therapy (HRT)
A Review on the International Position Paper on Women’s
Health and Menopause (Paoletti and Wenger 2003) defines
the original document, published in 2002, as a valuable
resource not only for healthcare professionals but also for
policy makers, scientists as well as individual women seeking
information on menopausal health. It defines menopause as
“the permanent cessation of menstruation resulting from the
loss of ovarian follicular activity”, emphasizing that it is a
normal event in a woman’s life, not a disease. However, aging
increases significantly the incidence of CVD and previous
observational studies suggested that postmenopausalVascular Health and Risk Management 2006:2(4) 471
Coronary artery disease in women
hormone replacement therapy (HRT) might prevent or reduce
heart disease as well as alleviate menopause symptoms
(Paoletti and Wenger 2003).
In that setting, many studies of IHD were analyzed by the
WISE workshop, which identified certain important issues
(Waters et al 2004). The researchers identified potential benefits
of ovarian hormones on the cardiovascular system, such as
antiatherogenic and vasodilator actions. They acknowledge
that estrogen increases coronary blood flow in response to
acetylcholine in post-menopausal women, prolongs exercise
time until the beginning of myocardial ischemia in these women
who have coronary disease, and increases fibrinolytic activity.
On the other hand, estrogen activates coagulation pathways,
presenting a final procoagulant effect, and increases C-reactive
protein levels, an independent predictor of future coronary
events (Waters et al 2004). The adverse vascular effects of
HRT might be associated with the last mentioned mechanism.
The WISE workshop mentioned several studies relating
CVD risks to HRT. The Heart Estrogen/progestin Replacement
Study (HERS) showed no difference for the primary end point
of coronary death or non-fatal AMI between post-menopausal
women using conjugated equine estrogen (CEE) and
medroxyprogesterone acetate (MPA) or placebo, in a 4.1-year
follow-up (Hulley et al 2002). The Estrogen Replacement and
Atherosclerosis (ERA) trial included women with CAD using
estrogen, estrogen plus MPA, or placebo in order to assess
minimum lumen diameter changes through coronary
angiography (Herrington et al 2000). Again no differences
were found. Women’s Angiographic Vitamin and Estrogen
(WAVE) trial randomized women to estrogen alone, estrogen
plus MPA or corresponding placebo (Waters et al 2002).
Women were also randomized to vitamin C and E supplements
or placebos. The change in minimum lumen diameter was
assessed and it was found that the risk of stenosis was
increased in women going through HRT.
Finally, the Women’s Health Initiative designed two parallel
clinical trials of HRT to determine whether CEE alone or
combined with MPA would reduce cardiovascular events in
mostly healthy postmenopausal women (The Women’s Health
Initiative Committee 2004). The estrogen + progestin trial
randomized over 16,000 intact uteri postmenopausal women
without known CAD to CEE with MPA or placebo and was
brought to an early closure, after a mean 5.2 years of follow-
up, due to an excess of occurrence of breast cancer among
women assigned to HRT, as well as an increase of risk of CHD,
stroke, venous thromboembolic disease (Rossouw et al 2002).
The Women’s Health Initiative estrogen-alone trial continued
until it reached an average of 6.8 years of follow-up (The
Women’s Health Initiative Committee 2004). It determined that
CEE increases the risk of stroke (HR 1.39; p = 0.007), decreases
the risk of hip fracture (HR 0.61; p = 0.01), and did not affect the
incidence of CHD (HR 0.91; CI 0.75–1.12) in postmenopausal
women. A possible reduction in breast cancer risk, despite the
estrogen + progestin results, met an HR of 0.77 (p = 0.06) and
requires further investigation. As the burden of incident
disease events was equivalent in the CEE and placebo groups,
indicating no overall benefit, CEE should not be recommended
for chronic disease prevention in postmenopausal women.
The major lessons from the WISE workshop document
were that HRT “is not useful for cardiovascular protection
and should not be used except for short term control of
menopausal symptoms” and that there are other means of
reducing vascular disease, for instance by use of statins and
angiotensin-converting enzyme inhibitors and even diet and
exercise. It also recommends further research into apparent
beneficial effects of endogenous estrogen.
Surgical interventions for obesity
Excess weight has been associated with higher mortality and
cardiovascular events (Melanson et al 2001; Ezzati et al 2002).
The United States had an important increase in the median
percent of adult obesity from 1991 to 2000, according to the
World Health Organization (Pan American Health Organization
2006). In 1990 the median percentage of the country’s adult
population that was obese (BMI > 30) by state was 12%. With
steady increases; in 2000, the median percentage reached 20%.
The mechanisms that explain the impact of obesity in CVD
include indirect effect on the vascular system through factors
such as dyslipidemia, hypertension, obstructive sleep apnea,
and insulin resistance, as well as increased leptin level,
enhanced systemic inflammation, and higher turnover of free
fatty acids with lipotoxic effects on myocardial cells (Eckel et
al 2002). Obesity is considered an independent risk factor for
CVD (Eckel 1997) and recommendations for weight loss begin
when BMI exceeds 25 kg/m
2 (Smith et al 2001). It has been
shown that women have a lower prevalence of being
overweight (BMI 25–29.9) than men, 25% vs 40%, but a higher
prevalence of obesity (BMI > 30), 25% vs 20%, respectively.
There are studies that have assessed the effect of weight loss
in CAD patients, but women-specific trials are few.
Liposuction is a very prevalent surgical procedure. The
American Society of Plastic Surgeons reported 324891
procedures during 2004 in the country, 90% of these in women
(American Society of Plastic Surgeons 2005). A study on theVascular Health and Risk Management 2006:2(4) 472
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effects of liposuction on CHD risk factors was developed
after the proposition that this procedure is a potential
treatment for the metabolic complications associated with
obesity (Klein et al 2004). The study evaluated insulin
sensitivity of various organs along with levels of
inflammatory mediators and other risk factors for CHD in 15
obese women before and 10 to 12 weeks after abdominal
liposuction of a mean of 10 kg of adipose tissue. It was
concluded that decreasing adipose tissue mass alone does
not achieve the metabolic benefits of weight loss, as
abdominal liposuction did not improve any of the markers in
study. However, the researchers responsible for the study
acknowledge positive outcomes from the surgical
intervention, not measured in their work (Klein et al 2004).
The removal of abdominal fat facilitates deambulation and
improves appearance, “which has important psychological
benefits” (Wood 2004).
Another common procedure is bariatric surgery, accounting
for over 52000 surgeries in 2003 in the United States (American
Society of Plastic Surgeons 2004). Studies assessed bariatric
surgery in obese patients with CAD. Lopez-Gimenez et al (2005)
determined the safety and efficacy of vertical, disconnected
Roux-en-Y gastric bypass. Patients with documented CAD
were compared with patients without CAD for a mean 2.5
years follow-up. Weight, BMI, fasting serum glucose,
glycosylated hemoglobin, and blood pressure all decreased
signifcantly (p < 0.001) post-operatively. Low-density
lipoprotein and triglycerides also decreased significantly (p <
0.01). Thus it was suggested that bariatric surgery was a
feasible method for treating patients with obesity and CAD
(Lopez Gimenez et al 2005).
The evidence from Program on the Surgical Control of
Hyperlipidemias (POSCH) trial seem to suggest that partial
ileal bypass as a modality would decrease overall mortality in
such patients (Buchwald et al 2002). A mean 18 years follow-
up demonstrated that the lipid profile normalization, guaranteed
by the surgical procedure, decreased overall mortality and
maintained a persistent and constant increase in life
expectancy. There was a 35% decrease in the mortality rate
from CHD combined with confirmed nonfatal AMI (p < 0.001),
as well as significant decreases in disease progression and in
treatment procedures such as percutaneous coronary
angioplasty and coronary artery bypass grafting. Further
evidence from POSCH trial with a follow up of 10 years seems
to support the view of the occurrence of a regression in
coronary artery atherosclerosis (Campo and Buchwald 1993).
The Swedish Obese Subjects (SOS) group also studied
obese patients with numerous CVD risk factors, assessing
the effects of bariatric surgery over a 2- and a 10-year period
(Sjöström et al 2004). It presented significant recovery rates
from many risk factors, such as obesity, diabetes,
hypertriglyceridemia, low levels of HDL cholesterol,
hypertension, and hyperuricemia, when conventionally
treated obese patients were compared to patients that had
undergone surgery. These rates were seen in both the short-
and the long-term follow-up. However, the incidence of
hypercholesterolemia and the rates of recovery did not differ
between the two groups over the 2- and the 10-year periods
(Sjöström et al 2004). Nonetheless, the latter findings were
not consistent with previous data presented in Nurses’
Health Study (Stampfer et al 2000), but the SOS group
believe that the long-term effects of maintained weight
loss cannot always be estimated from short-term
observations.
Acute coronary syndromes
After reviewing the results of several new studies on IHD to
understand the existing gender differences, the WISE
workshop brought together a number of recommendations
for practice. The document points to a similar or even better
outcome in women compared with men presenting ACS when
the pathophysiological differences can be overcome with early,
aggressive therapies (Hayes et al 2004).
The recommendations are based on the Rapid Early Action
for Coronary Treatment (REACT) study designed by the
NHLBI, in which multistrategy campaigns were tested to
reduce patient delay to seek care for ACS symptoms (Simons-
Morton et al 1998). It was emphasized that reducing time to
treatment can significantly reduce death and disability caused
by AMI (Simons-Morton et al 1998). This includes education
not only of healthcare providers, but also patients, individual
women and the general public about recognition of and
response to early symptoms.
The document has some direct recommendations. One of
them is patient awareness of symptoms: there are many
symptoms in addition to chest pain, pressure, or discomfort
and the symptom presentation may not be dramatic or sudden.
In addition, the recognition of symptoms by women and
healthcare providers requires further research about prodromal
syndromes and dissemination of not only public messages
but also information aimed at healthcare providers. Lastly, the
NHLBI document once more encourages better understanding
of all pathophysiological basis of ACS in women in order to
optimize treatment recommendations and develop earlier
symptom recognition.Vascular Health and Risk Management 2006:2(4) 473
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Preventive strategies and future
recommendations
The AHA has developed a document containing specific
guidelines for CVD prevention in adult women with a broad
range of cardiovascular risk (Mosca et al 2004). It highlights
the importance of preventing CVD, as two thirds of sudden
deaths in women have no previously recognized symptoms.
Additionally, prevention on CVD brings great benefits for the
prevention of non-coronary atherosclerosis, such as cerebro-
vascular disease and peripheral atherosclerosis.
The concept of CVD relies on a growing appreciation for the
existence of a continuum of CVD risk. AHA guidelines include an
illustrative table showing the spectrum of CVD risk and risk groups
(higher or lower risk) defined by their absolute probability of
having a coronary event in 10 years according to the Framingham
Risk Score for Women (Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults 2001). The
table aims to help healthcare providers determine the type of risk
intervention necessary in each case. Clinical recommendations
include interventions in lifestyle, major risk factors, and preventive
drug use as well as a list of useless or even harmful interventions
including HRT, antioxidant supplements, and aspirin use in low-
risk individuals. The priorities for prevention in practice are
carefully pointed out and separated according to each risk group.
The study recognizes several limitations such as individual
differences that do not fit into the recommendations. The
population used to generate these recommendations might not
reflect general patients’ characteristics. Moreover, there might
be variability in efficacy and effectiveness of various
interventions within the same risk intervention category. Finally,
even though the Framingham risk score may not apply equally
to all populations, it performs well within subgroups and AHA
intends to disseminate these guidelines for its better
implementation worldwide. However, it must be emphasized
that guidelines are definitely not a good substitute for clinical
judgment.
It is well recognized that implementation of these guidelines
may differ across countries and regions for cultural, medical,
and economic reasons and their application should also
consider individual factors such as frailty and life expectancy.
Clearly women, and particularly post-menopausal women,
remain at high risk for CHD. This may be justified at least in
part because women have been under-represented in clinical
outcome trials, tend to be under-treated in the clinical setting,
and might be misdiagnosed when their presenting symptoms
differ from those observed in men (Mosca et al 2004).
An observational study describing all symptoms of women
experiencing ischemic-like events compared with male
description could be helpful to relate these data to diagnostic
tests, outcomes, strategies of treatment, and forms of
investigating symptoms on future patients of both genders.
Furthermore, all the current information on CAD prevention,
diagnosis, and treatment available should be collected, brought
together, analyzed, and targeted to specific populations
regarding all social, cultural, and economic particularities in
the different regions, economic classes, and genders.
Information regarding all these aspects should not only be
disseminated to scientists and healthcare providers but also
among individual women, since patient information is known
to promote prevention, decrease time to treatment, and improve
patient prognosis.
Even though contemporary lifestyle and the increase of
life expectancy throughout the world have contributed to an
increase of CAD incidence, the progress in the scientific sphere
is the major factor responsible for holding back these figures.
As all pathophysiological mechanisms are not yet fully
understood, improvements in CAD knowledge are a promise
for future innovations on healthcare in order to positively
affect mortality rates in both women and men globally.
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